SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: dino who wrote (5789)10/2/1998 3:38:00 PM
From: Tokyo VD  Read Replies (1) | Respond to of 7041
 
Dino,

Thank you for your questions. Unfortunately, I don't have the answers at this time. I'll research your question and post an appropriate reponse.

The Zonagen royalty structure has been provided by reports from Wall Street.

Thank you for the good wishes.

Tokyo



To: dino who wrote (5789)10/2/1998 4:40:00 PM
From: Tokyo VD  Read Replies (2) | Respond to of 7041
 
Dino,

I hope this helps. ICOS will receive $75 million from Lilly as well as additional undisclosed milestone payments (which they are refusing to discuss).

ICOS will split the marketing cost with Lilly (this is a big unknown cost as well as another difference to the Zonagen/SGP deal) that will occur when the product hits the market. Estimated time line for market availability is late 2001.

Hope this answers your questions.

Tokyo


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News